ASP Isotopes (NASDAQ:ASPI) COO Sells $112,750.00 in Stock

Key Points

• COO Robert Ainscow sold 25,000 shares on March 6 at an average price of $4.51 for $112,750, reducing his direct stake to 1,512,817 shares (a 1.63% decrease) as disclosed in an SEC Form 4.
• QX results missed expectations: the company reported ($0.84) EPS versus ($0.14) expected, with very negative margins and ROE, although revenue beat at $33.32 million versus a $2.03 million estimate.
• Shares opened at $5.06 (up 12.9%), the stock has a market cap of about $560.9M and a negative PE, and analysts hold a consensus “Hold” with a $13 target while Weiss Ratings reaffirmed a “sell (d-)”.

ASP Isotopes Inc. (NASDAQ:ASPI - Get Free Report) COO Robert Ainscow sold 25,000 shares of the company's stock in a transaction on Friday, March 6th. The stock was sold at an average price of $4.51, for a total value of $112,750.00. Following the transaction, the chief operating officer directly owned 1,512,817 shares in the company, valued at $6,822,804.67. This represents a 1.63% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Robert Ainscow also recently made the following trade(s):

• On Friday, March 6th, Robert Ainscow sold 8,438 shares of ASP Isotopes stock. The stock was sold at an average price of $5.44, for a total value of $45,902.72.

ASP Isotopes Trading Up 12.9%

Shares of ASPI stock opened at $5.06 on Tuesday. The business's fifty day moving average price is $5.10 and its 200 day moving average price is $6.83. ASP Isotopes Inc. has a 1-year low of $3.92 and a 1-year high of $14.49. The firm has a market capitalization of $560.85 million, a PE ratio of -2.36 and a beta of 3.59. The company has a debt-to-equity ratio of 1.04, a current ratio of 6.14 and a quick ratio of 6.10.

ASP Isotopes (NASDAQ:ASPI - Get Free Report) last announced its quarterly earnings data on Friday, April 10th. The company reported ($0.84) earnings per share for the quarter, missing analysts' consensus estimates of ($0.14) by ($0.70). ASP Isotopes had a negative return on equity of 307.82% and a negative net margin of 734.14%.The business had revenue of $33.32 million for the quarter, compared to analyst estimates of $2.03 million. As a group, sell-side analysts forecast that ASP Isotopes Inc. will post -0.24 EPS for the current fiscal year.

Institutional Trading of ASP Isotopes

Institutional investors have recently bought and sold shares of the company. Rovida Investment Management Ltd boosted its position in ASP Isotopes by 45.5% during the third quarter. Rovida Investment Management Ltd now owns 3,200,000 shares of the company's stock worth $30,688,000 after purchasing an additional 1,000,000 shares in the last quarter. Caprock Group LLC purchased a new stake in ASP Isotopes during the third quarter worth $2,747,000. Sara Bay Financial purchased a new stake in shares of ASP Isotopes in the third quarter valued at $8,688,000. SPX Gestao de Recursos Ltda purchased a new stake in shares of ASP Isotopes in the third quarter valued at $1,054,000. Finally, Rathbones Group PLC lifted its position in shares of ASP Isotopes by 68.6% in the fourth quarter. Rathbones Group PLC now owns 399,599 shares of the company's stock valued at $2,138,000 after acquiring an additional 162,535 shares in the last quarter. 16.80% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Separately, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of ASP Isotopes in a report on Friday, March 27th. Two research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus target price of $13.00.

ASP Isotopes Company Profile

ASP Isotopes Inc, a development stage advanced materials company, focuses on the production, distribution, marketing, and sale of isotopes. It engages in the production and commercialization of Molybdenum-100, a non-radioactive isotope for the medical industry; Carbon-14; and Silicon-28. The company is also developing Quantum Enrichment technology to produce Ytterbium-176, Nickel-64, Lithium 6, Lithium7, and Uranium-235. ASP Isotopes Inc was incorporated in 2021 and is headquartered in Washington, District Of Columbia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.